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Abstract Tumor necrosis factor (TNF) has been shown to in- 
hibit the growth of some cell types and stimulate the proliferation 
of others by a mechanism that is not understood. In the present 
study, we investigated the effect of transfection of NIH-3T3 cells 
with either the basic fibroblast growth factor gene (bFGF) or the 
kaposi FGF gene (K-fgf) on the growth-modulatory effects of 
TNF. Our results show that transformation of cells with either 
gene leads to resistance to the growth-inhibitory effects of TNF. 
The K-fgfgene was found to be a more potent inducer of cellular 
resistance than the bFGF gene. The cellular resistance correlated 
with the inhibition of TNF-induced activation of phospholipase A 2 
and downmodulation of TNF receptors. Overall, our results indi- 
cate that both K-fgfand bFGF play an important role in suppres- 
sion of antiproliferative ffects of TNE 
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1. Introduction 
Tumor necrosis factor (TNF), a protein with a molecular 
mass of 17 kDa, originally described as a product of activated 
macrophages, has been shown to directly inhibit the growth of 
some tumor cells and stimulate the growth of others, whereas 
it has no affect on some tumor cells [1,2]. This difference has 
been assigned to manganese superoxide dismutase, glutathione, 
growth factors, and oncogenes [3,11]. 
Fibroblast growth factor (FGF) is a family of seven distinct 
heparin-binding polypeptides that control the growth of both 
normal and tumor cells. Among them, human basic FGF  
(bFGF) is a 155 amino acid protein that shares 50% amino acid 
sequence homology with products of kaposi FGF  (kFGF). 
bFGF  is an autocrine growth factor for a wide variety of tu- 
mors including melanoma, prostate, gliomas, and renal cell 
carcinoma [12-15]. Although, the role of the kFGF  gene (K-fg/) 
in the genesis of tumors in humans has not yet been established, 
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the transfection of NIH-3T3 cells with K-fgf induces tumori- 
genesis and metastasis [16]. Human bFGF differs from kFGF 
in that the former lacks the typical signal sequence for passage 
through the endoplasmic reticulum, whereas the latter encodes 
for a secreted protein with a molecular mass of approximately 
22 kDa. Secretion o fkFGF  has been shown to be a prerequisite 
for its ability to transform cells [17]. 
In this report, we investigated the role of an oncogenes K-fgf 
and bFGF on the antiproliferative effects of TNF. Our results 
indicate that transfection of cells with either gene induces resist- 
ance to the anticellular effects of TNF  and this is accompanied 
by a downmodulation of TNF  receptors and TNF-induced 
phospholipase A 2 (PLA2) activity. 
2. Materials and methods 
2.1. Materials 
Highly purified, bacteria-derived recombinant human TNF with a 
specific activity of 50 x 106 units/mg was kindly provided by Genentech 
(South San Francisco, CA). Polyclonal antibodies to human bFGF 
were kindly provided by Dr. Denis Gospadarowicz of the University 
of California, San Francisco, CA. 
2.2. Cells 
Mouse NtH 3T3 cells transfected with the retroviral vector pZip-Neo 
SV(X) alone, pZip Neo SV(X) containing a human bFGFcDNA insert, 
or pZipNeo SV(X) containing K-fglThst cDNA insert as described [181 
were kindly provided by Dr. Dan Rifkin of New York University 
Medical Center, New York, NY. Cells constitutively expressing the 
transfected vectors were selected by growth in the presence of G418 
(500 ¢tg/ml). As controls, cells transfected with the neomycin resistance 
vector alone were selected by the same procedure. These bFGF- and 
K-jg]:transfected cells which have been shown to acquire atransformed 
phenotype, xpress high levels ofbFGF and kFGF, respectively [18,19]. 
All cell types were routinely grown in Dulbecco's minimum essential 
medium (DMEM) supplemented with glutamine (1%), gentamicin (50 
,ug/ml), and fetal bovine serum (FBS) (10%) in a humidified incubator 
in 5% CO2 in air. Cells were tested for mycoplasma contamination using 
a DNA-based assay kit purchased from Gen-Probe (San Diego, CA). 
2.3. Cell growth inhibit&n 
For growth inhibition assays, cells (5 × 103/well) were plated over- 
night in 0.1 ml of DMEM with 10% FBS in 96-well Falcon plates. 
Thereafter, the medium was removed and a serial dilution of human 
TNF was layered in 0.1 ml of the medium. After 72 h of incubation at 
37°C, the medium was removed, and viable cells were monitored by 
crystal violet staining according to the procedure described [1], The 
relative cell viability was calculated as optical density in the presence 
of the test sample divided by optical density in the absence of the test 
sample (medium) and expressed as a percentage. 
2.4. Cell growth assays 
Cells (5 × 103/well) were plated in 1 ml of the medium (DMEM plus 
10% FBS) in 24-well Falcon plates. After incubation overnight in a CO2 
All rights reserved. 
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incubator at 37°C, the medium was removed, and TNF was layered in 
1 ml of the fresh medium. After different days of incubation, the me- 
dium was decanted off, and cells were counted by hemocytometer. All 
determinations were made in triplicate. 
For [3H]thymidine incorporation assays, cells were cultured and 
treated with TNF exactly the same way as indicated above for 3 days. 
During the last 6 h, [3H]thymidine (6.7 Ci/mmol; DuPont NEN Medical 
Products, Wilmington, DE) was added to each well (0.5 /~Ci/well). 
]'hereafter, the culture medium was removed, the wells were washed 
twice with phosphate-buffered saline (PBS), and the cells were detached 
by the addition of a solution of trypsin (0.5%) with EDTA (5.3 mM). 
The cell suspension was then harvested with the aid of a PHD cell 
harvestor (Cambridge Technology Inc., Watertown, MA) and lysed by 
washing with distilled water. Radioactivity bound to the filter was 
measured in a liquid scintillation counter (Model 1600 TR; Packard 
Instruments Co., Meriden, CT). 
2.5. Radioreceptor assay 
Receptor binding assays were carried out essentially as described 
previously [20]. 
2.6. Arachidonic acid release assays 
Arachidonic acid release assays were carried out according to the 
procedure previously described [21]. Briefly, cells (0.1 x 106/well) were 
plated in 12-well plates and labeled with [3H]arachidonic acid (0.1 
/ICi/well) by incubation overnight at 37°C, washed four times at 10-min 
intervals, and then incubated with TNF for 20 h at 37°C. Thereafter, 
the supernatants were removed, cleared of debris by centrifugation, and 
the amount of radioactivity released was determined by liquid scintilla- 
tion counting. The levels of total arachidonic acid incorporation i
untreated cells were determined by solubilization of cells with 2% so- 
dium dodecyl sulfate. 
3. Results 
We first investigated the antiproliferative effect of different 
concentrations of TNF  on NIH-3T3 cells transfected with ei- 
ther neo (control) or bFGFor K-fgfgenes (Fig. 1). The antipro- 
liferative effects of TNF  were examined by dye-uptake (upper 
panel) and the thymidine incorporation method (lower panel). 
These results how that exposure of control (neo) NIH 3T3 cells 
to 1.2 nM TNF for 72 h inhibited their growth by approxi- 
mately 80%, whereas the growth of bFGF transfected cells was 
inhibited by only 40%. The growth of K-fg)':transfected cells 
under these conditions, however, was not significantly affected 
by TNF. Thus, these results suggest hat K-fgf can induce a 
complete resistance to the antiproliferative effects of TNF, 
whereas only a partial resistance is observed with bFGF-trans- 
formed cells. The difference in the sensitivity to TNF  between 
K-fg]'and bFGF-transfected cells was more pronounced by the 
thymidine incorporation method than by the dye-uptake 
method. 
Since cells transfected with bFGF and K-fgfgrew at different 
rates than the control cells, we examined the effect of TNF on 
the growth rate of cells transfected with three different con- 
structs. The rate of cell growth in these experiments was exam- 
ined by the trypan blue exclusion method (Fig. 2). The results 
of these experiments indicate that the total growth of bFGF-and 
K-fgf-transfected cells on day 4 was approximately 3-fold and 
5-fold higher than control cells, respectively. Growth of control 
cells could be almost completely inhibited by 1.2 nM TNF 
(upper panel), whereas growth of bFGF-transfected cells would 
be only partially (approximately 50%) (middle panel) and the 
growth of K-fgf transfected cells only minimally inhibited 
(lower panel). Thus, the results of these experiments are consis- 
tent with the conclusion that K-fgf is capable of blocking the 
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Fig. 1. Antiproliferative effects of different concentrations of TNF 
against neo-, bFGF- and K-fgf-transfected murine NIH-3T3 cells. 
5 x 103 cells (0.1 ml) in 96-well plates were incubated with TNF at 37 ° C 
for 72 h, and then the relative cell viability was determined by staining 
with crystal violet (upper panel) or by thymidine incorporation (lower 
panel). The relative cell viability was determined asindicated in section 
2. All determinations were made in triplicate. 
antimitogenic effects of TNF. The resistance of transfected cells 
to TNF was maintained both in the presence and absence of 
serum (data not shown). 
To investigate the mechanism by which K-fgf and bFGF 
induce resistance to TNF, we examined the presence of TNF 
receptors on all three different cell types (Fig. 3). The specific 
binding of TNF  to bFGF- and K-fgf-transfected cells was about 
20% that of the control cells. The amount of binding in K-fgf- 
transfected cells was similar to that in bFGF-transfected cells. 
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(neo) cells was released in response to TNF within 20 h. Under 
these conditions, only a 10% release of the arachidonic acid was 
observed with K-fgf-transfected cells, thus suggesting its rela- 
tive resistance to TNF. With bFGF-transfected cells, however, 
the amount of arachidonic acid released was not significantly 
different from that of the control cells. The difference between 
K-fgf- and bFGF-transfected cells with respect o arachidonic 
acid release may be caused by the difference in the kinetics of 
production or their differential sensitivity as indicated by other 
methods. 
We also examined the morphological changes in neo-, bFGF- 
and K-fgf-transfected cells before and after treatment of cells 
with TNF (Fig. 4). There was a difference in the morphology 
of the three cell types untreated with TNF. The difference in 
the sensitivity between these cells to TNF  is also quite apparent. 
4. Discuss ion 
In the present studies, we demonstrate hat growth factors 
modulate the cell growth inhibitory property of TNF. The 
transfection of cells with either K- fgf  or bFGF genes induced 
resistance to the antiproliferative effects of TNF. The resistance 
w~s almost complete for cells carrying the K-fg)Cgene and par- 
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Fig. 2. The effect of TNF on the growth rate ofneo (upper panel), bFGF 
(middle panel) and K-fgo c (lower panel) -transfected NIH-3T3 cells. 
5 × 103 cells (1 ml) in 24-well plates were incubated for different dura- 
tions in the presence or absence of TNF (1.2 nM) at 37°C. Cell number 
was determined asdescribed in section 2. All determinations were made 
in triplicate. 
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total receptor density had decreased after transfection of cells 
with bFGF and K- fg f  
Because the growth inhibitory properties of TNF have been 
linked to the activation of PLA2 [21], we examined the effect 
of FGF  transfection on the ability of TNF  to induce the ara- 
chidonic acid release by activation of PLA 2. Approximately 
35% of the total arachidonic acid incorporated by the control 
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Fig. 3. Specific Binding of labeled TNF to neo-, K-fgf- and bFGF- 
transfected NIH-3T3 cells. 1 × 106 cells (0.1 ml) in 96-well plates were 
incubated with different concentrations of labeled TNF either in the 
presence (non-specific binding) or absence (total binding) of 100 nM 
unlabeled TNF for 1 h at 4°C, and thereafter cells were centrifuged, 
washed thrice, and cell-bound radioactivity counted. All determina- 
tions were made in triplicate. 
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Fig. 4. Morphological effects of TNF on the neo-, K-fgf- and b-FGF-transfected NIH-3T3 cells. Cells were exposed to TNF (1.2 nM) for 72 h and 
then photographed under the Nikon TMS microscope (× 100) on Tm~ 100 Kodak film, exposed at 100 ASA. 
tial for the bFGF gene. Our results also show that induction of 
resistance by both the growth factors downmodulated TNF 
receptors and PLA2 activity. 
How transfection of cells with bFGF and K-fgfgenes induces 
resistance to TNF and causes receptor modulation is not clear. 
Because the number of bFGF receptors/cell has been shown to 
be inversely proportional to the intracellular contents of bFGF, 
it suggests an autocrine downregulation f the receptors [18,22]. 
It is possible that downmodulation f bFGF receptors i linked 
to that of TNF receptors in some manner. Alternatively, bind- 
ing of bFGF to its receptors elicits tyrosine phosphorylation f 
several cellular substrates including the bFGF's  own receptors 
[23], thus suggesting that FGF  receptors belong to the tyrosine 
kinase receptor gene family. Previously, we have shown that 
transfection of cells with other tyrosine kinase receptor or re- 
ceptor activating ligands also cause resistance to TNF and is 
accompanied by downmodulation of the TNF receptor [8 11] 
analogous to bFGF and K-fgf How activation of a growth 
factor tyrosine kinase receptor induces resistance and receptor 
modulation is not clear. Since the ligand-induced trans- 
phosphorylation between different FGF receptors has been 
demonstrated [23], it is possible that TNF receptor or receptor- 
associated protein undergoes transphosphorylation in response 
to the activation of the growth factor receptor tyrosine kinase, 
which in turn leads to downregulation of TNF receptor and 
finally to induction of resistance to the cytokine. This hypoth- 
esis is supported by evidence that the activation of protein 
kinase C by phorbol esters downmodulates whereas inhibition 
of protein kinase C by staurosporin upmodulates the TNF 
receptors [24,25]. 
In the past, we have reported several glioma cell lines that 
are resistant to the antiproliferative effects of TNF [26]. Since 
glioma cells are known to express bFGF [13], it is possible that 
the TNF-resistance of these cells is in part caused by the over- 
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expression of the FGF. Overall, our results indicate that expres- 
sion of these growth factors by tumor cells protects them from 
the host defense system. Our results also imply that blocking 
the synthesis or action of these growth factors by their antibod- 
ies or with antisense oligodeoxynucleotides irected against it 
may have potential in overcoming the resistance to immune 
system cytokines uch as TNF in these tumor cells. 
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